

Elena Criscuolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7269340/publications.pdf>

Version: 2024-02-01

36
papers

1,172
citations

471061

17
h-index

433756

31
g-index

45
all docs

45
docs citations

45
times ranked

2421
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. <i>Molecular Therapy</i> , 2022, 30, 311-326.	3.7	54
2	Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 434-448.	1.9	50
3	Nanopore Recappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs. <i>Nucleic Acids Research</i> , 2022, 50, 3475-3489.	6.5	12
4	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. <i>Vaccines</i> , 2022, 10, 801.	2.1	13
5	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1232.	1.5	2
6	Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects. <i>Journal of Medical Virology</i> , 2021, 93, 2160-2167.	2.5	52
7	Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. <i>Pharmacological Research</i> , 2021, 163, 105255.	3.1	88
8	Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. <i>Emerging Microbes and Infections</i> , 2021, 10, 206-209.	3.0	74
9	Viral Respiratory Pathogens and Lung Injury. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	5.7	76
10	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.	1.5	12
11	Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021. <i>Virology Journal</i> , 2021, 18, 168.	1.4	36
12	The interferon landscape along the respiratory tract impacts the severity of COVID-19. <i>Cell</i> , 2021, 184, 4953-4968.e16.	13.5	165
13	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. <i>PLoS Pathogens</i> , 2021, 17, e1009878.	2.1	52
14	Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. <i>Clinica Chimica Acta</i> , 2021, 522, 144-151.	0.5	28
15	IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e829-e831.	2.2	13
16	A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6140-6156.	1.9	10
17	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. <i>Vaccines</i> , 2021, 9, 1357.	2.1	24
18	Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. <i>Virology Journal</i> , 2020, 17, 103.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. <i>Frontiers in Microbiology</i> , 2020, 11, 1704.	1.5	18
20	Interferon-Î²-1a Inhibition of Severe Acute Respiratory Syndromeâ€“Coronavirus 2 In Vitro When Administered After Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 722-725.	1.9	61
21	Phage Therapy: An Alternative to Antibiotics. , 2020, , 335-346.		0
22	Next Generation Vaccines for Infectious Diseases. <i>Journal of Immunology Research</i> , 2019, 2019, 1-2.	0.9	11
23	Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. <i>Journal of Immunology Research</i> , 2019, 2019, 1-13.	0.9	72
24	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. <i>Journal of Virology</i> , 2019, 93, .	1.5	21
25	Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle. <i>Antiviral Research</i> , 2018, 151, 71-77.	1.9	9
26	Role and potential therapeutic use of antibodies against herpetic infections. <i>Clinical Microbiology and Infection</i> , 2017, 23, 381-386.	2.8	11
27	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. <i>Antiviral Research</i> , 2017, 143, 48-61.	1.9	9
28	Bacteriophages and Their Immunological Applications against Infectious Threats. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	0.9	47
29	Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes. <i>Drug Discovery Today</i> , 2016, 21, 682-691.	3.2	16
30	Epitope Mapping by Epitope Excision, Hydrogen/Deuterium Exchange, and Peptide-Panning Techniques Combined with In Silico Analysis. <i>Methods in Molecular Biology</i> , 2014, 1131, 427-446.	0.4	7
31	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. <i>Antiviral Research</i> , 2014, 108, 94-103.	1.9	13
32	JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	16
33	Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-12.	3.3	26
34	Influenza B-Cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines. <i>Viruses</i> , 2012, 4, 3090-3108.	1.5	10
35	Neutralization Interfering Antibodies: A â€œNovelâ€“ Example of Humoral Immune Dysfunction Facilitating Viral Escape?. <i>Viruses</i> , 2012, 4, 1731-1752.	1.5	26
36	Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. <i>New Microbiologica</i> , 2012, 35, 399-406.	0.1	13